Fractional Laser + Tirbanibulin for Skin Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new method for treating skin cancer, specifically squamous and basal cell carcinomas. It examines the use of a fractional laser, either alone or with an ointment called tirbanibulin, to determine their effectiveness in treating cancer while preserving cosmetic appearance. The goal is to provide a less invasive alternative to surgery. Candidates for this trial include individuals with biopsy-confirmed squamous or basal cell carcinoma that has not been treated by other methods. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this innovative treatment.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that fractional laser treatments are generally well-tolerated by patients. One study reported common skin changes, such as redness in 74% of cases and changes in skin color in 30% of cases, without any serious side effects. This suggests that the treatment is generally safe, with side effects primarily affecting the skin.
For those using both fractional laser and tirbanibulin ointment, past patients have experienced positive outcomes. The absence of specific data on serious side effects suggests that the combination is likely safe, especially since the FDA has already approved tirbanibulin for certain skin conditions. Overall, these treatments appear to have a good safety record, with manageable side effects.12345Why are researchers excited about this trial's treatments?
Researchers are excited about these treatments because they combine fractional laser therapy with tirbanibulin ointment, potentially offering a powerful one-two punch against skin cancer. Unlike traditional treatments, such as surgical excision or cryotherapy, fractional laser therapy targets the cancerous tissue with precision, minimizing damage to surrounding healthy skin. Tirbanibulin, a newer topical agent, works by disrupting protein production in cancer cells, which could enhance the effectiveness of the laser treatment. This combination may provide a more targeted and less invasive option for patients, with the potential for quicker recovery and fewer side effects.
What evidence suggests that this trial's treatments could be effective for skin cancer?
This trial will compare the effectiveness of two treatment approaches for skin cancer. Research has shown that using fractional lasers with tirbanibulin ointment, which participants in one arm of this trial will receive, can effectively treat certain skin cancers, such as basal and squamous cell carcinomas. In one study, 30 skin cancers were successfully treated, demonstrating the potential benefits of this combination. Meanwhile, fractional lasers alone, which participants in another arm of this trial will receive, have improved skin appearance in 76% of patients, with many noticing better cosmetic results. Tirbanibulin ointment targets skin cells, enhancing the treatment's effectiveness. Overall, these treatments aim to reduce the need for surgery and improve skin appearance.12678
Who Is on the Research Team?
Bruce Robinson, MD
Principal Investigator
Bruce Robinson, MD
Are You a Good Fit for This Trial?
This trial is for individuals with biopsy-confirmed basal or squamous cell carcinomas of the skin that haven't been treated before. It's designed to find a less invasive treatment option that could help improve cosmetic outcomes.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive fractional laser therapy and may apply tirbanibulin ointment for five nights
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Fractional Laser
- Tirbanibulin Ointment
Trial Overview
The study tests fractional laser therapy followed by Tirbanibulin ointment application on skin cancer lesions. The lasers used are thulium and erbium, and the ointment is applied over five nights post-treatment.
How Is the Trial Designed?
2
Treatment groups
Active Control
Treatment of nodular or invasive carcinomas will be with fractional laser followed by a course of Klisyri ointment.
Treatment of superficial or in situ carcinomas will be with fractional laser only.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Bruce Robinson, MD
Lead Sponsor
Citations
An Analysis of Laser Therapy for the Treatment of ...
Although prognosis is generally excellent, approximately 4% metastasize, and 1.5% to 2% result in mortality.
Treatment of superficial basal cell carcinoma and ...
Cosmesis was rated as “better than before treatment” by 76% (23/30) of patients and “same as before treatment” by the remainder. Fig 1 Squamous cell carcinoma ...
Utilizing fractional lasers and tirbanibulin ointment to treat ...
Studies have found that non-ablative fractional laser therapy can be an effective treatment for actinic keratoses [19]. Researchers also found ...
Image Guidance is Associated with Improved Freedom ...
This study demonstrates that IGSRT is associated with remarkably low recurrence rates, which are statistically significantly improved from the previous ...
Ablative fractional laser with topical fluorouracil effective for ...
The overall treatment success rate was 79% (95% CI, 67-96). The success rate for those with SCC in situ was 92% and the success rate was 67% for ...
Updated results of 3050 non-melanoma skin cancer (NMSC ...
Hernández-Machin et al. reported 5-year absolute LC rates of 94.4% for BCC lesions and 92.7% for SCC lesions. With these results, the authors ...
Randomized controlled trial of fractionated laser ...
Though the treatments resulted in significant levels of wounding (Figure 6B), minimal discomfort and no scarring was noted in the participants. Side effects ...
Treating Basal and Squamous Cell Carcinomas With ...
Every skin cancer will be treated with two wavelengths (1550nm and 1927nm) of a non-ablative fractional laser. What is the study measuring? Primary Outcome ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.